This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Best GARP Stocks to Beat Pandemic-Led Market Inefficiency
by Urmimala Biswas
The unprecedented global health crisis is providing a psychological shock to the investment world.
NextGen Virtual Visits Supports Women Health During COVID-19
by Zacks Equity Research
Capital Women's Care is set to expand NextGen's (NXGN) women's healthcare services during the coronavirus emergency.
Patterson Companies (PDCO) Q4 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results reflect dismal performance by Dental and Animal Health segments.
Masimo (MASI) Boosts Product Portfolio with New Solution
by Zacks Equity Research
Masimo (MASI) unveils Masimo Sleep to help consumers better understand their quality of sleep.
Amedisys Rides on Hospice Arm Expansion Amid Coronavirus Woes
by Zacks Equity Research
Amedisys (AMED) benefits from the recent acquisitions of hospice care providers, Asana Hospice, RoseRock Healthcare and Compassionate Care Hospice.
Medtronic's Evolut TAVI Gets CE Mark for Low-Risk Patients
by Zacks Equity Research
Medtronic's (MDT) Evolut system shows a lower rate of the composite of all-cause death or disabling stroke with TAVI at 30 days.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect solid performance at Dental segment.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, intense competition remains a woe.
Zimmer Biomet Adds New Features to mymobility with Apple Watch
by Zacks Equity Research
Zimmer Biomet (ZBH) expands mymobility digital platform by leveraging Apple's ecosystem to enhance patients' post-operative care.
Allscripts' (MDRX) Veradigm Partners with PAN Foundation
by Zacks Equity Research
This partnership between Allscripts (MDRX) and PAN Foundation is expected to boost patient outcomes.
Thermo Fisher Grows on Coronavirus Diagnostic Tests Amid Crisis
by Zacks Equity Research
Thermo Fisher (TMO) is optimistic about ramped up production for its COVID-19 diagnostic test to meet growing global demand.
NuVasive Launches Reline 3D for Pediatric Patients Globally
by Zacks Equity Research
Other than Reline 3D, NuVasive's (NUVA) Reline System portfolio has products like Reline Open, Reline MAS, Reline Trauma and Reline Small Stature.
Here's Why You Should Hold on to NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as solid international business.
Medtronic Partners Foxconn to Scale Up Ventilator Production
by Zacks Equity Research
Medtronic (MDT) enters into a partnership with Foxconn with an aim of providing 10,000 PB560 ventilators in the United States over the next year amid the pandemic-led surge in demand for the same.
PerkinElmer's Tie-Up to Boost Health Outcomes in Africa
by Zacks Equity Research
PerkinElmer's (PKI) partnership with ASH likely to boost newborn screening in underserved populations for better health outcomes in Africa.
Henry Schein Dental Software Arm May Rebound Despite Pandemic
by Zacks Equity Research
Henry Schein (HSIC) also seems to be upbeat about its dental technology business, Henry Schein One.
Walgreens' Retail Pharmacy Grows Amid Coronavirus Crisis
by Zacks Equity Research
Walgreens' (WBA) tie-ups with Alphabet's life sciences and healthcare segment, Verily on multiple projects related to chronic ailments buoy optimism.
DGX vs. AMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. AMED: Which Stock Is the Better Value Option?
Illumina Takes Over BlueBee, Fortifies NGS Data Processing
by Zacks Equity Research
With this acquisition, the cloud capability of BlueBee's platform will help Illumina (ILMN) to lower the cost of storing, sharing and managing the company's huge volumes of genomic data.
Tandem Diabetes Gets Expanded Indication for Insulin Pump
by Zacks Equity Research
Tandem Diabetes (TNDM) receives clearance for expanded indication for pediatric use of t:slim X2 insulin pump with Control-IQ, paving the way for simpler diabetes management in younger patient pool.
Accuray's New CyberKnife S7 System to Boost Patient Care
by Zacks Equity Research
Accuray's (ARAY) newly launched CyberKnife S7 System will enable clinicians to provide best possible care to their patients through new capabilities.
Myriad Genetics' Prolaris Receives Favorable Coverage Policies
by Zacks Equity Research
Myriad Genetics (MYGN) paves the way for bringing more prostate cancer patients under the purview of Prolaris testing through their health plan.
Medtronic Gets CE Mark for Micra AV Pacer to Treat AV Block
by Zacks Equity Research
With the approval of Medtronic's (MDT) Micra AV, more pacemaker patients will be eligible for a new treatment option.
Abbott's Libre 2 iCGM Gets FDA Nod to Better Manage Diabetes
by Zacks Equity Research
Abbott's (ABT) FDA-cleared FreeStyle Libre 2 iCGM is the only available system to continuously transmit glucose data with real-time alarms.
Encompass Health to Build Rehabilitation Hospital in Illinois
by Zacks Equity Research
Encompass Health (EHC) plans to build a rehabilitation facility in Illinois to serve the local community. The healthcare home will be launched in 2022 spring and complement other units in the area.